Best Growth Stocks to Buy for October 1st

Zacks highlighted Centene, ATI and BP as Rank #1 (Strong Buy) stocks after current-year consensus EPS estimates rose 7.0%, 15.1% and 22.6%, respectively, over the past 60 days. The article is analyst-driven stock-selection commentary rather than new company disclosures, implying limited near-term market impact despite positive estimate-revision momentum.

Analysis

This is a low-information, promotional screen rather than a fundamental catalyst; estimate revisions alone are typically already reflected in short-term momentum signals. The actionable distinction is whether revisions are driven by durable operating assumptions rather than commodity prices, reserve releases, or one-time medical-cost timing. No position should be initiated solely on the ranking absent confirmation in next-quarter guidance and cash-flow estimates.

ATI has the clearest potential 6-18 month fundamental setup: aerospace-grade titanium/nickel capacity remains qualification-constrained, giving it greater pricing persistence than broad metals peers if commercial-aircraft build rates hold. A widening spread between ATI's aerospace mix and spot industrial-metal pricing would support margin expansion; the main falsifier is a Boeing/Airbus production-rate reduction or evidence that working-capital consumption offsets EBITDA growth. Long ATI versus short XME is preferable to an outright materials beta exposure.

BP's earnings sensitivity is more likely macro-driven than company-specific. Higher upstream and trading cash flow can support distributions, but the equity's rerating is capped if crude strength also lifts refining feedstock costs or if investors continue to discount its transition-capex and balance-sheet trajectory relative to XOM/CVX. For CNC, the key issue is medical-loss-ratio normalization and Medicaid redetermination enrollment/mix—not consensus EPS momentum; an apparently favorable revision cycle can reverse sharply on a single adverse utilization or rate-acuity update.

The contrarian view is that simultaneous positive revisions across energy, aerospace materials, and managed care do not form a coherent cross-sector growth signal. They may instead reflect separate late-cycle drivers—commodity pricing, aircraft supply bottlenecks, and insurer reserve/timing assumptions—which creates elevated reversal risk around earnings. QBTS has no discernible linkage to the underlying setup and should be excluded from any inference drawn from this item.

Key Decisions for Investors

• Watch, do not trade, the generic ranking signal over the next 1-3 months; require post-earnings upward FCF guidance and at least one additional consensus revision cycle before adding exposure.
• Initiate a 3-6 month pair: long ATI / short XME, sized beta-neutral, only if aerospace order commentary and full-year EBITDA guidance are maintained. Target 10-15% relative upside; exit if ATI cuts shipment or margin guidance, or Boeing/Airbus reduce production assumptions.
• Maintain BP as a tactical energy-beta holding rather than a standalone earnings-revision long. Use a 1-3 month long BP / short XLE hedge only if Brent remains above the level embedded in consensus; take risk down on a 10% Brent decline or a deterioration in buyback/free-cash-flow guidance.
• Keep CNC on an earnings watchlist rather than add ahead of utilization and Medicaid-rate disclosures. Consider a long CNC / short HUM or UNH pair only after management confirms medical-cost trend and enrollment mix; a medical-loss-ratio guide increase is the thesis stop.